Evaluation of the natural immunity in pups inoculated with a modified-live canine parvovirus type 2b (CPV-2b) strain

A. Pratelli, M. Altamura, D. Buonavoglia, M. Pepe, A. Tafaro, A. Lembo, F. Cirone, M. Tempesta, E. Jirillo, C. Buonavoglia

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Three pups 2-4 months old were vaccinated subcutaneously with the modified live canine parvovirus, CPV-2b/29-97 strain. During an observation period of two weeks pups remained clinically health, exhibiting a vigorous post-vaccinal active serological response (haemoagglutinating inhibiting antibody titers for CPV-2 ranging from 1:2560 to 1:5120 at 21 days post inoculation). Phagocytosis and killing of Candida albicans exerted by polymorphonuclear cells and monocytes did not undergo significant modifications 3-6 days post vaccination up to 30 days. Antibacterial activity mediated by peripheral blood lymphocytes (Salmonella typhi was used as a target) was slightly, but not significantly decreased 3 days post vaccination. Conclusively, in pups the CPV type 2b vaccine seems to be safe as far as natural immune responses are concerned, while its immunogenicity is preserved.

Original languageEnglish
Pages (from-to)451-464
Number of pages14
JournalImmunopharmacology and Immunotoxicology
Volume22
Issue number3
Publication statusPublished - 2000

Fingerprint

Canine Parvovirus
Salmonella
Lymphocytes
Candida
Innate Immunity
Vaccination
Blood
Vaccines
Health
Salmonella typhi
Antibodies
Candida albicans
Phagocytosis
Monocytes
Observation

ASJC Scopus subject areas

  • Health, Toxicology and Mutagenesis
  • Immunology
  • Pharmacology
  • Toxicology

Cite this

Pratelli, A., Altamura, M., Buonavoglia, D., Pepe, M., Tafaro, A., Lembo, A., ... Buonavoglia, C. (2000). Evaluation of the natural immunity in pups inoculated with a modified-live canine parvovirus type 2b (CPV-2b) strain. Immunopharmacology and Immunotoxicology, 22(3), 451-464.

Evaluation of the natural immunity in pups inoculated with a modified-live canine parvovirus type 2b (CPV-2b) strain. / Pratelli, A.; Altamura, M.; Buonavoglia, D.; Pepe, M.; Tafaro, A.; Lembo, A.; Cirone, F.; Tempesta, M.; Jirillo, E.; Buonavoglia, C.

In: Immunopharmacology and Immunotoxicology, Vol. 22, No. 3, 2000, p. 451-464.

Research output: Contribution to journalArticle

Pratelli, A, Altamura, M, Buonavoglia, D, Pepe, M, Tafaro, A, Lembo, A, Cirone, F, Tempesta, M, Jirillo, E & Buonavoglia, C 2000, 'Evaluation of the natural immunity in pups inoculated with a modified-live canine parvovirus type 2b (CPV-2b) strain', Immunopharmacology and Immunotoxicology, vol. 22, no. 3, pp. 451-464.
Pratelli, A. ; Altamura, M. ; Buonavoglia, D. ; Pepe, M. ; Tafaro, A. ; Lembo, A. ; Cirone, F. ; Tempesta, M. ; Jirillo, E. ; Buonavoglia, C. / Evaluation of the natural immunity in pups inoculated with a modified-live canine parvovirus type 2b (CPV-2b) strain. In: Immunopharmacology and Immunotoxicology. 2000 ; Vol. 22, No. 3. pp. 451-464.
@article{2b5d79ec7aaa417989a70ab28e09a446,
title = "Evaluation of the natural immunity in pups inoculated with a modified-live canine parvovirus type 2b (CPV-2b) strain",
abstract = "Three pups 2-4 months old were vaccinated subcutaneously with the modified live canine parvovirus, CPV-2b/29-97 strain. During an observation period of two weeks pups remained clinically health, exhibiting a vigorous post-vaccinal active serological response (haemoagglutinating inhibiting antibody titers for CPV-2 ranging from 1:2560 to 1:5120 at 21 days post inoculation). Phagocytosis and killing of Candida albicans exerted by polymorphonuclear cells and monocytes did not undergo significant modifications 3-6 days post vaccination up to 30 days. Antibacterial activity mediated by peripheral blood lymphocytes (Salmonella typhi was used as a target) was slightly, but not significantly decreased 3 days post vaccination. Conclusively, in pups the CPV type 2b vaccine seems to be safe as far as natural immune responses are concerned, while its immunogenicity is preserved.",
author = "A. Pratelli and M. Altamura and D. Buonavoglia and M. Pepe and A. Tafaro and A. Lembo and F. Cirone and M. Tempesta and E. Jirillo and C. Buonavoglia",
year = "2000",
language = "English",
volume = "22",
pages = "451--464",
journal = "Immunopharmacology and Immunotoxicology",
issn = "0892-3973",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Evaluation of the natural immunity in pups inoculated with a modified-live canine parvovirus type 2b (CPV-2b) strain

AU - Pratelli, A.

AU - Altamura, M.

AU - Buonavoglia, D.

AU - Pepe, M.

AU - Tafaro, A.

AU - Lembo, A.

AU - Cirone, F.

AU - Tempesta, M.

AU - Jirillo, E.

AU - Buonavoglia, C.

PY - 2000

Y1 - 2000

N2 - Three pups 2-4 months old were vaccinated subcutaneously with the modified live canine parvovirus, CPV-2b/29-97 strain. During an observation period of two weeks pups remained clinically health, exhibiting a vigorous post-vaccinal active serological response (haemoagglutinating inhibiting antibody titers for CPV-2 ranging from 1:2560 to 1:5120 at 21 days post inoculation). Phagocytosis and killing of Candida albicans exerted by polymorphonuclear cells and monocytes did not undergo significant modifications 3-6 days post vaccination up to 30 days. Antibacterial activity mediated by peripheral blood lymphocytes (Salmonella typhi was used as a target) was slightly, but not significantly decreased 3 days post vaccination. Conclusively, in pups the CPV type 2b vaccine seems to be safe as far as natural immune responses are concerned, while its immunogenicity is preserved.

AB - Three pups 2-4 months old were vaccinated subcutaneously with the modified live canine parvovirus, CPV-2b/29-97 strain. During an observation period of two weeks pups remained clinically health, exhibiting a vigorous post-vaccinal active serological response (haemoagglutinating inhibiting antibody titers for CPV-2 ranging from 1:2560 to 1:5120 at 21 days post inoculation). Phagocytosis and killing of Candida albicans exerted by polymorphonuclear cells and monocytes did not undergo significant modifications 3-6 days post vaccination up to 30 days. Antibacterial activity mediated by peripheral blood lymphocytes (Salmonella typhi was used as a target) was slightly, but not significantly decreased 3 days post vaccination. Conclusively, in pups the CPV type 2b vaccine seems to be safe as far as natural immune responses are concerned, while its immunogenicity is preserved.

UR - http://www.scopus.com/inward/record.url?scp=0033856044&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033856044&partnerID=8YFLogxK

M3 - Article

C2 - 10946825

AN - SCOPUS:0033856044

VL - 22

SP - 451

EP - 464

JO - Immunopharmacology and Immunotoxicology

JF - Immunopharmacology and Immunotoxicology

SN - 0892-3973

IS - 3

ER -